Update on diagnosis and treatment of pulmonary alveolar microlithiasis  

Update on diagnosis and treatment of pulmonary alveolar microlithiasis

在线阅读下载全文

作  者:Hui-Ying Wang Ni-Ya Zhou Xu-Yan Yang 

机构地区:[1]Department of Allergy, the Second Affiliated Hospital,College of Medicine,Zhejiang University [2]Department of Rheumatology, the Second Affiliated Hospital, College of Medicine, Zhejiang University

出  处:《World Journal of Respirology》2014年第3期26-30,共5页世界呼吸病学杂志

基  金:Supported by Zhejiang Provincial Science and Technology Project,No.2011C37073

摘  要:Pulmonary alveolar microlithiasis(PAM)(MIM265100)is a rare disease characterized by the diffuse deposit of microlithiasis in alveolar spaces.PAM could occur worldwide with high prevalence in Asia and Europe.Familial occurrence indicates its autosomal recessive trait and the SLC34A2 gene was identified as the responsible gene for the disease.In spite of the versatile mutation sites in patients from other countries,exon 7and exon 8 might be the most liable gene in Chinese and Japanese patients.Most mutations caused the premature termination of proteins and produced truncated proteins,leading to the blocking of the recycling and degrading of outdated surfactant which is full of phospholipids.The most outstanding clinical feature of PAM is the discrepancy between the paucity of symptoms and the degree of pulmonary involvement.Diagnosis is easy to establish based on typical chest radiograph image and nuclear medicine improves its early diagnosis and active evaluation.Pathology of the unique intra-alveolar lamellar microliths gives strong support for diagnosis.No effective treatment is considered valid currently.However,lung transplantation is effective for advanced-stage patients,and long term treatment of disodium etidronate seems promising.Pulmonary alveolar microlithiasis(PAM)(MIM265100) is a rare disease characterized by the diffuse deposit of microlithiasis in alveolar spaces. PAM could occur worldwide with high prevalence in Asia and Europe. Familial occurrence indicates its autosomal recessive trait and the SLC34A2 gene was identified as the responsible gene for the disease. In spite of the versatile mutation sites in patients from other countries, exon 7 and exon 8 might be the most liable gene in Chinese and Japanese patients. Most mutations caused the premature termination of proteins and produced truncated proteins, leading to the blocking of the recycling and degrading of outdated surfactant which is full of phospholipids. The most outstanding clinical feature of PAM is the discrepancy between the paucity of symptoms and the degree of pulmonary involvement. Diagnosis is easy to establish based on typical chest radiograph image and nuclear medicine improves its early diagnosis and active evaluation. Pathology of the unique intra-alveolar lamellar microliths gives strong support for diagnosis. No effective treatment is considered valid currently. However, lung transplantation is effective for advanced-stage patients, and long term treatment of disodium etidronate seems promising.

关 键 词:PULMONARY ALVEOLAR MICROLITHIASIS SLC34A2 MUTATION CHEST COMPUTED tomography Treatment 

分 类 号:R[医药卫生]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象